; (ii) to be safe in cosmetic products under specified conditions of use of tolerances; or (iii) to be not safe in cosmetic products; (B) the timeline for such review; (C) the types of scientific evidence, clinical studies, data, or other information used to make such a determination; (D) whether, and to what extent, the review of the ingredient or nonfunctional constituent (or category thereof) resulted in cosmetic products being reformulated or removed from the market; and (E) the impact the review and determination had on consumer use and access to such product; and (2) an analysis of the ingredient, nonfunctional constituent (or category thereof) review conducted under such section 608, including— (A) the resources used by the Secretary in reviewing ingredients and nonfunctional constituents (or categories thereof), including the effects of the program on other cosmetic safety activities of the Secretary; (B) the impact of such section on innovation and consumer access to cosmetic products; and (C) whether any improvements to the program under such section 608 are necessary for increasing the efficiency and effectiveness of the review of cosmetic ingredients, nonfunctional constituents, or categories thereof. 103. Good manufacturing practices for cosmetics (a) In general Chapter VI of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 361 et seq.), as amended by section 102, is further amended by adding at the end the following: 610. Good manufacturing practices for cosmetics (a) In general The Secretary shall— (1) review national and international standards for cosmetic good manufacturing practices that are in effect on the date of enactment of the Cosmetic Safety Enhancement Act of 2019